KGbio is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside the US/Canada, Western Europe and China. The business model revolves around in-licensing novel biologics and select biosimilars in oncology and high-specialty therapeutic areas (typically pre-IND or early clinical stage), with the objective to out-license them in target geographies after finishing clinical development as well as regulatory and reimbursement approvals.   Platforms of interest currently include Fc-fusion proteins, antibodies, bispecifics, ADCs, cell therapies and therapeutic vaccines.  The company is backed by Asian pharma companies Kalbe (market cap US$5.5 billion) and Genexine (market cap US$1.3 billion) and US private equity giant General Atlantic (AUM US$ 78 billion).

Biotechnology

Life Sciences

Therapeutics

KGbio

Sie Djohan

Atiya A.

Steven Amadeus

Amalia Indri Senoadji

Seng Chuen Tan

The Business Development and Licensing team at KGbio is responsible for identifying, evaluating, and negotiating partnerships for innovative biologics and biosimilars in oncology and high-specialty areas. They work on in-licensing promising candidates at early clinical stages and strategize on out-licensing opportunities in targeted markets once the products advance through development and regulatory approvals. This team plays a crucial role in expanding KGbio's portfolio and facilitating the global reach of its therapeutic innovations.

Business Development and Licensing

Business Development and Licensing

About

Team members